Chemical biology approaches to understand interindividual variability in carboxylesterase activity

Active Project Grant Awarded

Award ID
R15GM152890
Recipient
Awarding agency
Obligated
$355,211

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 91% complete
Place of performance
Charleston, IL 61920, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Michael w. Beck, eastern illinois university before an orally delivered drug can reach its target in the body IT must first be absorbed by the digestive system and pass through the liver via the hepatic portal system. During this process, the drug is metabolized by enzymes in these tissues. This metabolism controls the bioavailability of oral drugs; thus the activity and expression levels of these enzymes is important. Human carboxylesterases (cess) are highly expressed in the intestines and the liver and therefore play a key role in controlling the metabolism of many drugs. The overall activity of cess, however, can be drastically different from person to person. This interindividual variability has been shown to influence the metabolism and, in some cases, clinical outcomes of patients treated with drugs that are substrates for carboxylesterase 1 (CES1). The factors that contribute to CES1 activity variation have not been fully uncovered, despite the established importance of CES1 in drug metabolism. We believe this lack of knowledge is due to the scarcity and limitations of currently available approaches to study CES1 activity in live samples. To address these challenges, this proposal aims to develop and optimize fluorogenic probes that can specifically report on CES1 activity in live samples. These probes will be deployed to generate chemical biology-based approaches that can rapidly evaluate small molecules for their potential to interfere with CES1 activity and determine the influence of CES1 genetic polymorphisms on CES1 activity. The probes and methods created in this proposal will enable rapid analysis of CES1 activity under different conditions in live cells. The application of these approaches to study factors that influence CES1-mediated drug metabolism will reveal new risk factors for ineffective treatment with CES1-substrate drugs. Overall, the studies proposed here uncover factors that modulate CES1 activity resulting in safer and more effective treatments with CES1-substrate drugs while providing an excellent training platform for undergraduate students in modern biomedical research.

Quick answers

Who received award R15GM152890?

R15GM152890 was awarded to Eastern Illinois University by National Institute of General Medical Sciences (National Institutes of Health) on February 1, 2024.

How much is award R15GM152890 worth?

$355,211 has been obligated on R15GM152890.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login